How a Single Amino Acid Pathway May Steer Autoimmune Disease

One of the most abundant amino acids in the human body is quietly emerging as a central player in some of medicine’s most stubborn diseases. Glutamine, long dismissed by many immunologists as little more than cellular fuel, sits at the heart of a metabolic circuit that appears to decide whether immune cells stay calm or turn against the body’s own tissues. A new review published in the Journal of Translational Medicine argues that this circuit, known as the glutamine-glutamate metabolic axis, may hold the key to understanding and eventually treating autoimmune rheumatic diseases, a group of chronic inflammatory conditions that includes rheumatoid arthritis and systemic lupus erythematosus.

The review, authored by Yujing Li and Zhuoli Zhang of Peking University First Hospital together with Hong Yu of the University of Texas Health Science Center at San Antonio, synthesizes a growing body of experimental and clinical evidence linking nutrient metabolism to immune dysfunction. Its central claim is deceptively simple: the way immune cells process glutamine and convert it into glutamate is not a passive background process but an active regulatory network that shapes immune cell fate, differentiation, and effector function. When that network is disrupted, the result may be the loss of self-tolerance and persistent immune activation that define autoimmune rheumatic diseases.

To appreciate why this matters, it helps to understand what the glutamine-glutamate axis actually does. Glutamine is the most plentiful free amino acid in plasma, and immune cells consume it voraciously. Once transported into a cell, glutamine can be converted to glutamate through a reaction catalyzed by the enzyme glutaminase, releasing ammonia in the process. Glutamate then feeds into multiple downstream routes: it can be further converted to alpha-ketoglutarate, which enters the tricarboxylic acid cycle to generate energy and biosynthetic intermediates; it can supply nitrogen for the production of other amino acids, nucleotides, and the antioxidant glutathione; and it can participate in non-essential amino acid synthesis that rapidly dividing cells require. In effect, the axis is a metabolic junction connecting fuel supply, building-block production, and redox balance.

What has become increasingly clear over the past decade is that this junction does far more than keep cells alive. Metabolic reprogramming, the wholesale shift in how a cell generates and spends energy, is now recognized as a prerequisite for immune cell activation and lineage commitment. A resting lymphocyte and an activated lymphocyte look almost nothing alike on the inside, and much of that difference is driven by changes in glutamine flux. The same is true of monocytes and macrophages, the innate immune cells that patrol tissues and coordinate inflammatory responses. By controlling the availability of alpha-ketoglutarate and other metabolites, the glutamine-glutamate axis influences epigenetic modifications, signaling cascades, and transcriptional programs that determine which genes a cell expresses and, ultimately, what that cell becomes.

The review emphasizes that this regulation operates across multiple immune cell populations. In lymphocytes, glutamine metabolism supports the proliferation and differentiation needed for adaptive immune responses, and alterations in flux can bias cells toward inflammatory or regulatory fates. In monocytes and macrophages, the axis helps govern polarization, the process by which these cells adopt pro-inflammatory or tissue-repairing identities. Because autoimmune rheumatic diseases involve both arms of immunity, dysregulated glutamine metabolism provides a mechanistic bridge that can explain how nutrient utilization becomes entangled with immune pathology in conditions as heterogeneous as rheumatoid arthritis, lupus, and related disorders.

Autoimmune rheumatic diseases themselves are a formidable clinical challenge. They are characterized by the immune system’s loss of tolerance to the body’s own components, producing chronic inflammation that damages joints, skin, kidneys, blood vessels, and other organs. Current therapies, ranging from conventional immunosuppressants to modern biologics, have transformed outcomes for many patients, but they do not work for everyone, and long-term immunosuppression carries significant risks. This therapeutic gap has pushed researchers toward immunometabolism, the study of how metabolic pathways govern immune behavior, in the hope that rewiring cellular metabolism might calm inflammation more precisely than broadly blunting the immune system.

Accumulating experimental and clinical evidence, the authors write, associates dysregulated glutamine-glutamate metabolism with immune dysregulation and tissue injury in rheumatic diseases. In practical terms, this means that abnormalities in how immune cells take up glutamine, convert it to glutamate, and channel the resulting metabolites into energy production and biosynthesis appear to track with the inflammatory damage seen in patients. The review frames this axis as an immunometabolic regulatory network that links nutrient utilization and cellular metabolic remodeling to immune cell fate and function, positioning it as a candidate mechanism underlying the chronic immune activation that keeps these diseases smoldering.

The therapeutic implications are considerable. If the glutamine-glutamate axis drives immune pathology, then targeting it offers a strategy that is conceptually distinct from existing drugs. Rather than blocking a single cytokine or surface receptor, metabolic interventions could alter the fundamental operating conditions of overactive immune cells, starving them of the biosynthetic support they need to sustain inflammation while potentially sparing cells that are behaving normally. The authors suggest that a deeper understanding of these immunometabolic mechanisms may facilitate the development of precision metabolism-based therapeutic strategies for autoimmune rheumatic diseases, an approach that would tailor metabolic interventions to the specific metabolic fingerprints of a patient’s immune cells.

Precision is the operative word. Glutamine is not simply a villain to be eliminated; it is essential for gut integrity, kidney function, and the survival of many cell types, including regulatory immune cells that restrain autoimmunity. Blanket depletion of glutamine would almost certainly cause collateral harm. The challenge, and the opportunity, lies in identifying which enzymatic steps, transporters, and downstream pathways within the axis are selectively exploited by pathogenic immune cells, and in designing drugs or dietary strategies that exploit those vulnerabilities. The review’s comprehensive mapping of the axis across lymphocytes and monocytes/macrophages is intended to provide exactly that kind of mechanistic roadmap for future drug development.

The work also reflects a broader shift in how immunology is practiced. For much of the twentieth century, immune cells were studied primarily as signaling machines, with metabolism treated as housekeeping. The immunometabolism revolution has inverted that view, revealing that metabolic state and immune identity are two sides of the same coin. The glutamine-glutamate axis, sitting at the intersection of nutrition, bioenergetics, and gene regulation, exemplifies this new paradigm. As Li, Yu, and Zhang’s synthesis makes clear, understanding how a single amino acid and its conversion product orchestrate the behavior of the very cells that attack our own tissues may prove to be one of the more consequential ideas in modern rheumatology, and a promising frontier for patients whose diseases remain beyond the reach of current therapies.

Subject of Research: The role of the glutamine-glutamate metabolic axis in regulating immune cell function and autoimmune rheumatic disease pathogenesis

Article Title: The glutamine-glutamate metabolic axis in autoimmune rheumatic diseases: immunometabolic regulation and therapeutic potential

Article References: Li, Y., Yu, H., & Zhang, Z. (2026). The glutamine-glutamate metabolic axis in autoimmune rheumatic diseases: immunometabolic regulation and therapeutic potential. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08904-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08904-6

Keywords: glutamine, glutamate, immunometabolism, autoimmune rheumatic diseases, rheumatoid arthritis, systemic lupus erythematosus, metabolic reprogramming, lymphocytes, macrophages, inflammation, precision medicine, Journal of Translational Medicine